Researchers report that DNA changes linked to certain blood cancers may emerge years before routine blood tests reveal abnormalities. The study focuses on cancers such as acute myeloid leukemia and myelofibrosis, suggesting that early molecular signals could precede clinical detection.
The sources describe this as a potential shift toward earlier monitoring. Rather than relying solely on standard blood-count results, the findings indicate that genomic alterations in blood may provide earlier warning of progression. Both outlets frame the work as evidence that some patients could show cancer-related DNA changes long before clinicians see corresponding changes through conventional testing.
While the reports emphasize the possible time gap between molecular changes and blood-test detection, they also imply a need for further validation of how such DNA markers could be used in practice, including which changes are most informative and how they should guide follow-up or treatment decisions.
